Analysis of the Western European Biomarkers Market in Drug Discovery and Development

Increasing Applications of Biomarkers are Driving Growth

Regular Price: USD 4,950

Special Price USD 4,455

10% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 4,455

PAY BY INVOICE

Be the first to review this product

Biomarkers will certainly change the way healthcare is provided. They are being increasingly used in early drug development and for clinical use as well, boosting their demand. The penetration of biomarkers in various therapeutic applications, the impact of market trends and dynamics are analysed in this study. This research service offers market overview, Market Engineering measurements, revenue forecasts, company profiling and key trends for the market and its segments, namely, genomics, proteomics, metabolomics and imaging biomarkers.

Table of Contents

Executive SummaryKey FindingsScope and SegmentationKey Questions This Study Will AnswerMarket Engineering MeasurementsCEO’s PerspectiveKey Companies to WatchMarket Attractiveness by Region3 Big PredictionsMarket OverviewMarket BackgroundMarket OverviewMarket Segmentation Market Segmentation (continued) Defining Future Healthcare TrendsCompetitive PlaybookNew Market OpportunitiesNew Market Opportunities (continued)Merger, Acquisition and Partnership AssessmentMerger, Acquisition and Partnership Assessment (continued)Drivers, Restraints and Trends—Total Biomarkers Market in Drug Discovery and DevelopmentMarket DriversMarket RestraintsImpact Mapping of Drivers and RestraintsForecast and Trends—Total Biomarkers Market in Drug Discovery and DevelopmentMarket Engineering MeasurementsForecast AssumptionsRevenue ForecastRevenue Forecast DiscussionPer cent Revenue Forecast by SegmentRevenue Forecast by SegmentBiomarkers Market Outlook in EuropePer cent Revenue by Region Emerging TrendsTechnology TrendsMarket TrendsEmerging TrendsEmerging Trends (continued) Emerging Trends (continued) Technology Lifecycle AnalysisGenomics Segment BreakdownMarket Engineering MeasurementsRevenue ForecastRevenue Forecast DiscussionRevenue Forecast Discussion (continued)Genomics Segment—Metrics AnalysisGrowth Opportunity Analysis for Genomics in Drug Discovery and Companion DiagnosticsGrowth Opportunity Analysis for Genomics in Drug Discovery and Companion Diagnostics (continued)Growth Opportunity Analysis for Genomics in Drug Discovery and Companion Diagnostics (continued)Proteomics Segment BreakdownMarket Engineering MeasurementsRevenue ForecastRevenue Forecast DiscussionProteomics Segment—Metrics AnalysisGrowth Opportunity Analysis for Proteomics in Drug Discovery and Companion DiagnosticsGrowth Opportunity Analysis for Proteomics in Drug Discovery and Companion Diagnostics (continued)Growth Opportunity Analysis for Proteomics in Drug Discovery and Companion Diagnostics (continued)Growth Opportunity Analysis for Proteomics in Drug Discovery and Companion Diagnostics (continued)Metabolomics Segment BreakdownMarket Engineering MeasurementsRevenue ForecastRevenue Forecast discussionRevenue Forecast Discussion (continued)Metabolomics Segment—Metrics AnalysisGrowth Opportunity Analysis for Metabolomics in Drug Discovery and Companion DiagnosticsGrowth Opportunity Analysis for Metabolomics in Drug Discovery and Companion Diagnostics (continued)Growth Opportunity Analysis for Metabolomics in Drug Discovery and Companion Diagnostics (continued)Imaging Segment BreakdownMarket Engineering MeasurementsRevenue ForecastRevenue Forecast DiscussionImaging Segment—Metrics AnalysisGrowth Opportunity Analysis for Imaging in Drug Discovery and Companion DiagnosticsGrowth Opportunity Analysis for Imaging in Drug Discovery and Companion Diagnostics (continued)Biomarker Research ClustersUK BiobankUK Biobank (continued)UK Biobank (continued)UK Biobank (continued)UK Biobank (continued)The Biomarkers ConsortiumThe Biomarkers Consortium (continued)The Biomarkers Consortium (continued)Other Biomarker Research ProjectsOther Biomarker Research Projects (continued)Regional AnalysisMarket Attractiveness by RegionRegional Analysis—The United KingdomRegional Analysis—GermanyRegional Analysis—FranceRegional Analysis—ItalyRegional Analysis—SpainRegional Analysis—BeneluxRegional Analysis—ScandinaviaKey Companies to WatchAepodia S.A.AffymetrixAlmac GroupArgutus Medical Limited (EKF Diagnostics Group)AROS Applied Biotechnology A/SBio-Rad Laboratories, Inc. BioSystems InternationalBiovica International ABDiagenic ASADNAVision SAEpigenomics AGEpistem PlcEurofins ScientificIndivumed GmbHMetabometrixPronota NVProtagen AGProteome SciencesProteoSys AGQIAGENRocheThermo Fisher ScientificThe Last WordThe Last Word—3 Big PredictionsThe Last Word—DiscussionThe Last Word—Discussion (continued)The Last Word—Discussion (continued)Legal DisclaimerAppendixDrivers ExplainedDrivers Explained (continued)Drivers Explained (continued)Restraints ExplainedRestraints Explained (continued)Restraints Explained (continued)List of Other Companies in Biomarkers Research, Development and/or ServicesList of Other Companies in Biomarkers Research, Development and/or Services (continued)List of Other Companies in Biomarkers Research, Development and/or Services (continued)Decision Support Database Decision Support Database (continued) Decision Support Database (continued) Additional Sources of Information on DiabetesMarket Engineering MethodologyLearn More—Next Steps




Related Research

Release Date : 17-Jul-17

Region : North America

Release Date : 13-Sep-16

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.